Somewhat Favorable News Coverage Somewhat Unlikely to Impact Halyard Health (HYH) Stock Price

News articles about Halyard Health (NYSE:HYH) have trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Halyard Health earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 46.3510704878943 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

NYSE HYH opened at $46.12 on Monday. Halyard Health has a 12 month low of $35.24 and a 12 month high of $50.99. The company has a current ratio of 2.98, a quick ratio of 2.74 and a debt-to-equity ratio of 0.45. The company has a market cap of $2,163.95, a P/E ratio of 19.63, a P/E/G ratio of 5.40 and a beta of 1.62.

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.23. Halyard Health had a net margin of 5.82% and a return on equity of 6.98%. The business had revenue of $428.10 million for the quarter, compared to analyst estimates of $413.94 million. During the same quarter last year, the business earned $0.50 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. sell-side analysts predict that Halyard Health will post 0.96 EPS for the current fiscal year.

Several equities research analysts have commented on HYH shares. ValuEngine upgraded shares of Halyard Health from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. Zacks Investment Research upgraded shares of Halyard Health from a “hold” rating to a “buy” rating and set a $53.00 price objective on the stock in a research note on Thursday, January 4th. Finally, KeyCorp upgraded shares of Halyard Health from a “sector weight” rating to an “overweight” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Halyard Health presently has an average rating of “Buy” and a consensus target price of $49.33.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Halyard Health (HYH) Stock Price” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Insider Buying and Selling by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with's FREE daily email newsletter.

Leave a Reply